Trial Profile
Relapse Rates Among Patients With Multiple Sclerosis Who Switch From Glatiramer Acetate To Fingolimod: A Retrospective study by MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Glatiramer acetate
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Jun 2015 New trial record
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.